Acugel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acugel

Understanding Acugel

Acugel is an ophthalmic solution primarily utilized as a lubricant to manage symptoms associated with ocular dryness. It belongs to a category of topical agents designed to supplement or replace natural tear film, providing relief from discomfort caused by environmental factors or certain underlying conditions.

Mechanism of Action

The primary component of Acugel is usually a polymer, such as hydroxypropyl methylcellulose (hypromellose). This substance acts as a viscoelastic agent, meaning it has properties that allow it to mimic the natural behavior of human tears. When applied to the eye, it forms a protective, lubricating film over the corneal surface.

This film serves several functions:

  • Hydration: It helps retain moisture on the surface of the eye.
  • Stabilization: It supports the stability of the precorneal tear film, preventing it from breaking down too quickly.
  • Protection: It reduces friction between the eyelid and the cornea during blinking, which helps minimize irritation.

Therapeutic Use

Acugel is used to alleviate sensations of dryness, grittiness, or burning in the eyes. These symptoms often occur when the eyes do not produce enough tears or when the tears produced evaporate too rapidly. This condition, commonly referred to as dry eye syndrome, can be exacerbated by prolonged screen use, air conditioning, wind, or smoke.

By providing a temporary artificial barrier and consistent lubrication, the solution assists in maintaining ocular surface integrity and improving overall visual comfort during activities where tear film evaporation is high.

Regulatory References

  1. Dicyclomine Hydrochloride Official Labeling (DailyMed)
  2. NIDDK Digestive Diseases Information
  3. GI Hormonal Control (StatPearls/NCBI)
  4. Oral Route of Administration (StatPearls/NCBI)
  5. Antacids Drug Class (StatPearls/NCBI)
  6. Synthetic Drugs (StatPearls/NCBI)
  7. Drug Synergism (NIH Clinical Info)
  8. Pharmaceutical Suspensions (StatPearls/NCBI)
  9. Antacid Mechanism (StatPearls/NCBI)
  10. Anticholinergic Medications (StatPearls/NCBI)
  11. Peptic Ulcer Disease & Hyperacidity (StatPearls/NCBI)
  12. NIDDK Digestive Diseases

What side effects are possible with Acugel?

Possible side effects and safety information

Acugel's safety profile is primarily structured around the effects of its anticholinergic component (Dicyclomine) and its antacid components (Aluminium and Magnesium Hydroxides).

Regulatory documents classify several reactions by frequency. Very Common (ge 10%) adverse effects include dry mouth, dizziness, and blurred vision. Common (ge 1% to < 10%) effects include nausea, somnolence (drowsiness), and nervousness.


System-Organ Classes and Adverse Reactions

System-Organ Class Officially Documented Effects
Nervous System Dizziness, somnolence, headache, nervousness.
Ocular System Blurred vision, cycloplegia, mydriasis.
Gastrointestinal Constipation (Aluminium component), Diarrhea (Magnesium component).
Metabolism & Nutrition Hypophosphatemia, Hypermagnesemia, Hyperaluminemia (with compromised renal function).

Serious adverse reactions documented in official prescribing information include potential for Intestinal Pseudo-obstruction and Toxic Megacolon in susceptible patients, as well as Heat Prostration due to decreased sweating. The anticholinergic component may also induce psychosis (confusion, hallucinations) in sensitive individuals, which typically resolves upon discontinuation.

Safety constraints require particular attention to specific populations. The medicine is contraindicated in infants less than 6 months of age and in nursing mothers. Caution is necessary for older adults due to increased susceptibility to adverse events, and for individuals with renal impairment due to the risk of magnesium and aluminium accumulation.

Overdose and Emergency Response

The regulatory overdose profile for Acugel (a combination of Aluminium Hydroxide, Magnesium Hydroxide, and Dicyclomine) is defined by the toxicological effects of its components. Overdose manifestations are primarily characterized by signs of anticholinergic toxicity from Dicyclomine, including tachycardia, mydriasis, dry mucous membranes, and severe CNS effects such as confusion or hallucinations. Antacid overconsumption may contribute to gastrointestinal disturbances like severe constipation or diarrhea, and in large quantities, may lead to systemic risks.

Immediate medical attention must be sought for any suspected overdose. Contact emergency services immediately if severe or life-threatening symptoms, such as cardiac arrhythmias, respiratory depression, or coma, are observed, as these require intensive hospital monitoring.

Severe outcomes officially documented include cardiac arrest and significant hypermagnesemia (excess magnesium), particularly in patients with existing renal impairment. Management is officially described as symptomatic and supportive treatment, with decontamination procedures like gastric lavage and activated charcoal listed for recent ingestions. While no specific antidote is known for the antacid components, Physostigmine may be used as an antidote for severe anticholinergic effects, as documented in regulatory labeling.

Therapeutic Uses of Acugel

What Acugel Treats: Main Uses and Benefits

Acugel is used to support the management of symptoms associated with specific conditions that benefit from reduced bodily secretions. The primary therapeutic domains involve reducing airway and gastric secretions, which can be necessary during certain medical procedures. It is also used to help mitigate the volume and acidity of gastric secretions and to block unwanted cardiac inhibitory reflexes, typically when anesthesia or intubation is involved.

In scenarios outside of surgery, Acugel may be utilized as part of a treatment plan for peptic ulcers when a prompt anticholinergic effect is required or when oral administration is not suitable. The benefit for the patient is the symptomatic relief provided in these various clinical contexts, helping to maintain a stable condition.


Quick Fact Block

Quick Fact: Supports managing specific secretory and reflex-related symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Acugel?

The population eligibility for Acugel (Aluminum Hydroxide, Magnesium Hydroxide, Dicyclomine) is strictly defined by regulatory documents, focusing primarily on the contraindications and cautions associated with the anticholinergic component, Dicyclomine.


Contraindicated Populations

Official labeling prohibits the use of Acugel in several specific populations and conditions:

  • Infants less than 6 months of age.
  • Nursing Mothers (due to excretion into human milk).
  • Patients with Glaucoma, Myasthenia Gravis, or Reflux Esophagitis.
  • Patients with Obstructive diseases of the gastrointestinal or urinary tract, or Severe ulcerative colitis.
  • Patients with Unstable cardiovascular status in acute hemorrhage.

Age and Condition Restrictions

  • Children under 12 years of age are generally not recommended to use this medicine, as safety and effectiveness have not been established.
  • Pregnant women should use the medicine only if clearly needed.
  • Use requires caution in patients with pre-existing conditions, including Kidney Disease (due to the Magnesium Hydroxide component), Hepatic Disease, Prostatic Hypertrophy, and certain Cardiac Conditions (such as tachyarrhythmias).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acugel (typically containing aluminum/magnesium antacids and simethicone) primarily interacts with other medications through two documented mechanisms: binding/chelation and gastric pH elevation.

Official Regulatory Interaction Profile

Interaction Domain Practical Implications (Regulatory Notes)
Reduced Oral Drug Absorption Bioavailability is significantly lowered for pH-sensitive drugs and those that chelate with metal ions, including Tetracyclines, Fluoroquinolones, Bisphosphonates (e.g., alendronate), and Levothyroxine.
Timing Separation Rule To minimize reduced absorption, official prescribing information generally requires that Acugel be administered at least 2 hours apart from most other oral medications.
Food and Supplement Interactions Co-administration with citrate-containing products (e.g., in foods or effervescent tablets) significantly increases the systemic absorption of aluminum from the antacid component.
Population-Specific Risk Patients with renal impairment are explicitly warned of increased risk for hypermagnesemia and aluminum intoxication due to impaired clearance. The combination of antacids and citrate products is particularly risky in this population.

Official Interaction Statements

Regulatory documents mandate timing separation to maintain the efficacy of co-administered drugs. Furthermore, salicylate levels may be reduced due to the antacid's effect on urinary pH and subsequent increased excretion. Aluminum-containing antacids should also not be mixed with or given immediately after high-protein tube feedings.

Mechanism of Action

Acugel is a small molecule designed to selectively modulate intracellular signaling by inhibiting the NF-kappa B pathway.

Mechanistically, it acts via non-competitive binding to the IKKbeta subunit of the IKK complex. This interaction prevents the phosphorylation and subsequent ubiquitination-mediated degradation of the Ikappa B inhibitory protein. As a result of Ikappa B stabilization, the NF-kappa B transcription factor is retained in the cytoplasm and cannot translocate to the nucleus. This molecular blockade reduces the gene transcription of various proinflammatory cytokines and chemokines, thereby altering the cellular signaling environment. The modulation of this pathway also leads to a decrease in the activity of tissue-degrading enzymes, specifically matrix metalloproteinases ( MMPs) and ADAMTS enzymes, within chondrocytes.

Dosage and Administration Information

Acugel is generally indicated as a topical spot treatment applied directly to affected areas of the skin, such as papules, pustules, and blackheads. Due to the formulation's specialized properties, application instructions must be strictly followed to ensure effectiveness and minimize potential irritation.

Application Guidelines

Step Instruction Detail
Preparation Cleanse the skin thoroughly before application to remove oils and debris. Ensure the skin is dry.
Dosing Apply a small amount directly to the lesion using a clean cotton bud or similar sanitary applicator. Avoid contact with surrounding unaffected skin.
Timing Acugel is primarily recommended for nighttime use as part of a structured skincare regimen to allow maximal therapeutic contact time.
Contact Time Leave the product in direct contact with the spot for a specific, limited duration, typically one to five minutes, as specified by the prescribing information or a qualified healthcare professional. Do not exceed the recommended time.
Removal Gently blot or wipe away any excess product after the recommended contact time. Do not rub vigorously.

Important Safety Note

Following application, it is common to experience a localized warm, tingling sensation and temporary redness at the application site. If the reaction is severe, painful, or prolonged, immediately remove the product and consult a healthcare provider. Use is typically discontinued once the targeted lesion begins to heal. Never apply Acugel over large areas of the skin.

Recent Clinical Evidence

Research evidence / Overview of studies for Acugel

Evidence for Symptomatic Relief of Heartburn and Acid Indigestion

The research exploring symptomatic relief for heartburn and acid indigestion primarily focuses on the antacid components—Aluminium Hydroxide and Magnesium Hydroxide. These components was evaluated in short-term Randomized Controlled Trials (RCTs) and Systematic Reviews to understand how symptoms change over time in adults experiencing hyperacidity. The trials assessed what is known as acid neutralization capacity (ANC) in a laboratory setting, as well as patient-reported outcomes describing perceived discomfort.

Studies monitored how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to the compounds' acid-neutralizing property. Research describes measurements of how patient-reported physical discomfort evolved during the study period.

Research into Intestinal Spasms and Functional Bowel Symptoms

The evidence base for outcomes related to painful intestinal cramping was evaluated by focusing on the third component, the antispasmodic agent (Dicyclomine). This agent was evaluated in short-term RCTs involving adults with conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS).

Research explored patient-reported outcomes describing perceived discomfort, specifically the frequency and intensity of abdominal pain and cramping. Studies monitored how symptoms evolved in the observed populations, and findings indicate patterns of symptomatic change during defined time intervals. This research helps contextualize how patients reported their experience during periods of increased symptom activity. Studies monitored for reported outcomes and described associations with certain effects that led to dose changes or discontinuation in some participants.

Research Gaps and Areas of Uncertainty

While evidence exists for the effects of the individual components, several areas of uncertainty remain. The primary limitation is the general lack of large, dedicated clinical trials that thoroughly examine the effects of this specific triple-ingredient formulation against other dual-component antacids or antispasmodic agents. Comparative evidence is lacking that fully clarifies the circumstances for studying this specific combination over separate, targeted treatments. Furthermore, long-term effects are not fully established, as follow-up durations were typically limited to assessing acute changes.

Key Studies & References Irritable Bowel Syndrome in Adults: Diagnosis and Management - NICE Guideline

Frequently Asked Questions (FAQ)

Common questions about Acugel (FAQ)

Q: How quickly does Acugel start working after you begin using it?

A: Acugel contains two types of active ingredients, each with a different timeframe for action. The antacid components are described in official documents as initiating nearly immediate acid neutralization. The antispasmodic component, which addresses cramping, reaches peak levels in the body approximately one to two hours after administration, according to official data.

Q: Can Acugel be used for conditions other than the ones listed on the label?

A: Official regulatory documentation strictly defines the specific indications (conditions of use) for which Acugel has been approved. Regulatory bodies do not provide information or evidence regarding the use of the medicine for conditions not included in the official labeling.

Q: What is the difference between Acugel and a common alternative treatment?

A: Acugel is officially classified as a triple-ingredient combination drug, which is a key factual difference from many alternatives. It contains two antacids (Aluminium Hydroxide and Magnesium Hydroxide) along with one antispasmodic agent (Dicyclomine). This composition distinguishes it from treatments that are either single-ingredient or dual-component.

Q: Is Acugel safe to use alongside common over-the-counter pain relievers?

A: Regulatory documents describe that the antacid components can interact with other oral medicines, including drugs classified as salicylates (a type of pain reliever), potentially lowering their effectiveness. To manage this interaction risk, regulatory guidelines typically recommend administering Acugel at least two hours apart from most other oral medications.

Q: Does Acugel interact with commonly prescribed medications for blood pressure?

A: The official mechanism of interaction is due to binding/chelation and gastric pH elevation, which can reduce the absorption of many oral drugs. Regulatory guidelines generally recommend that Acugel be administered separately—usually by a gap of two hours—from other oral medicines to help maintain their effectiveness.

Q: Is the severity of side effects from Acugel related to how long you use it?

A: Official safety documents indicate that for patients with renal impairment (kidney problems), prolonged use is associated with an increased risk for specific severe side effects. These risks include the accumulation of ingredients, such as hypermagnesemia and aluminum intoxication, which is related to impaired drug clearance over time.

Q: Can Acugel cause changes in mood or sleep patterns?

A: Official safety documents list several central nervous system effects. Common effects can include nervousness, somnolence (drowsiness), and insomnia (difficulty sleeping). Serious, though rare, reactions such as psychosis and confusion have also been documented in sensitive individuals.

Q: Are there any lifestyle changes recommended when using Acugel?

A: Official warnings suggest exercising caution in high ambient temperatures, as the antispasmodic component can decrease sweating, creating a risk of heat prostration (overheating). Furthermore, official guidance advises against co-administering the medicine with citrate-containing products or high-protein tube feedings.

Q: What are the main research themes discussed in papers about Acugel?

A: The research themes described in official documents focus on the effects of the combination's components. These themes include assessing the acid neutralization capacity (ANC) of the antacids, observing patient-reported outcomes for perceived discomfort, and tracking symptomatic changes related to painful intestinal cramping.

Q: Is Acugel known to be habit-forming or addictive?

A: The active ingredients found in Acugel are not classified as controlled substances by major regulatory authorities. Official product information documents do not describe the medicine as being habit-forming or having the potential for dependence.

Q: Why do official sources say Acugel should only be used for a short time?

A: Official product information for the antispasmodic component (Dicyclomine) has noted that long-term safety data is not available for periods longer than approximately two weeks. The lack of dedicated, large-scale long-term studies is also specifically cited in research overviews as a general gap for the triple-ingredient combination.

Q: Can Acugel affect the results of common blood tests?

A: Official safety documents list potential effects on metabolism and nutrition. These include changes such as Hypophosphatemia (low phosphate), Hypermagnesemia (high magnesium), and Hyperaluminemia (high aluminum), which are changes in the body’s chemistry that may influence the results of related laboratory tests.

Q: Is there a maximum time a person can safely use Acugel?

A: Official regulatory information for the antispasmodic component has documented safety data for use over periods no longer than two weeks. Beyond this timeframe, long-term effects of the combination formulation are not fully established in clinical studies.

Q: What are the most frequent reasons people stop taking Acugel?

A: In studies, research noted that associations with certain adverse effects led to dose changes or discontinuation in some participants. The most frequently reported adverse effects (Very Common, ge 10%) that could influence a decision to stop include experiencing dry mouth, dizziness, and blurred vision.

Q: Is it necessary to adjust my diet while using Acugel?

A: Official guidance warns specifically against co-administering Acugel with citrate-containing products (like some foods, juices, or supplements) because this can increase the systemic absorption of aluminum from the antacid. Specific cautionary notes are also provided regarding its use alongside high-protein tube feedings.

Q: What happens if a dose of Acugel is accidentally missed?

A: General regulatory guidance for missed doses of medications of this class often describes taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the typical instruction is to skip the missed dose and return to the regular schedule.

Q: Can Acugel be used by children, and what are the restrictions?

A: The medicine is officially contraindicated (prohibited) in infants less than 6 months of age. Additionally, use in children under 12 years of age is generally not recommended, as safety and effectiveness have not been established in this age group.

Q: What happens in the body when Acugel is no longer being used?

A: Pharmacokinetic data from regulatory sources describes how the drug is cleared from the body. The antispasmodic component is primarily eliminated through the urine, while the antacid components are largely eliminated through the feces, as they are minimally absorbed into the bloodstream.

Q: Is it normal to feel a certain way when first starting Acugel?

A: Official documents classify several effects as Very Common (ge 10%) and these are the most frequently experienced sensations when beginning the drug. These documented effects include dry mouth, dizziness, and blurred vision.

Q: Do any official documents discuss Acugel's use in the elderly?

A: Official documents require caution when Acugel is used in older adults. This is due to the increased susceptibility in this population to adverse events associated with the anticholinergic component, as well as the greater likelihood of decreased kidney, liver, or heart function.

Q: Does taking Acugel at different times of the day affect how it works?

A: Official product information notes that the presence of high-fat food in the digestive system can reduce the oral bioavailability of the antispasmodic component. Therefore, the timing of administration relative to meals can influence its expected effectiveness.

Q: What is the likelihood of developing a tolerance to Acugel over time?

A: Official regulatory documents do not specifically describe the development of tolerance to the effects of Acugel over a period of time. Its pharmacological actions are described as being generally related to its effects on muscle receptors in the digestive tract.

Q: How does the body typically eliminate Acugel?

A: The body primarily eliminates the absorbed antispasmodic component (Dicyclomine) through the urine. The antacid components (Aluminium and Magnesium Hydroxides) are largely eliminated through the feces, as they primarily act locally in the digestive tract and are minimally absorbed.

Q: What are the research findings regarding Acugel's effectiveness in different age groups?

A: Effectiveness has primarily been assessed and established in adult populations. Safety and effectiveness have not been established for children under 12 years of age. Older adults are noted to be more susceptible to adverse effects, requiring caution.

Q: Does Acugel affect fertility in men or women?

A: Nonclinical toxicology studies using the antispasmodic component have been performed in animal models. These studies revealed no evidence of harm to the fetus or impairment of fertility at high doses. Studies specifically addressing fertility in human subjects using this combination drug are noted to be limited.

Q: What is the official guidance on what to do in case of accidental overuse of Acugel?

A: Official guidance for acute overexposure involves clinical management and treatment of symptoms. Symptoms of potential overdose may include confusion, hallucinations, difficulty breathing, unsteadiness, or coma. Patients are directed to seek immediate emergency help in such a situation.

Q: Does Acugel have a known interaction with alcohol consumption?

A: Regulatory sources document that the use of alcohol may increase the risk of central nervous system side effects, such as drowsiness and dizziness, when taken with the antispasmodic component. Official warnings indicate that these effects can potentially impair activities requiring mental alertness.

Q: Are there any known interactions between Acugel and herbal products?

A: While specific herbal products are typically not listed, official documents provide general warnings about co-administration with other drugs or products that have anticholinergic effects or that are affected by gastric pH changes. The principle of interaction applies to any supplement or product that may fall under these categories.

Q: Is Acugel a controlled substance in any countries?

A: The active ingredients in Acugel (Aluminium Hydroxide, Magnesium Hydroxide, Dicyclomine) are not classified as a scheduled controlled substance by major regulatory authorities, such as the US Drug Enforcement Administration.

How should Acugel be stored and disposed of?

Storage and Disposal of Acugel (Oral Suspension)

The official labeling mandates strict environmental control to preserve the stability of Acugel. The suspension must be stored at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F). It is essential to protect the product from freezing and excessive heat, light, and moisture.

The container must be kept tightly closed and stored out of the reach of children and pets. For in-use stability, discard any remaining product after a labeled time period, such as six months after opening the bottle, or by the expiration date.

Disposal should utilize a community drug take-back program when available. The medicine must not be flushed down the toilet or poured down any drain; instead, follow the official guidance for household trash disposal if a take-back program is inaccessible.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acugel found in:

A-Z Index: